Inspira Technologies Oxy BHN (IINN) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Inspira Technologies Oxy BHN Ltd. announced aggressive promotion plans for its ART100 device in the U.S. and other markets, following FDA clearance. The company aims to capture a share of the $19 billion mechanical ventilation market with its next-gen INSPIRA ART (Gen 2) technology, designed to oxygenate blood directly, potentially without intubation. Inspira also highlighted its strategic milestones including multi-site deployment of ART100 and advancement of its HYLA blood sensor and VORTX blood delivery system.
For further insights into IINN stock, check out TipRanks’ Stock Analysis page.